It’s been a terrible few weeks for Roche, with the Swiss pharma reporting today that its breast cancer drug failed in a Phase 3 trial critical to help it meet its multibillion-dollar sales forecasts. Last week, its Zealand-partnered obesity drug underwhelmed, and at the end of February, it said it will end work on a Duchenne drug.